Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?

zacks.com · 2026-07-24

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

TickrTrends take: Quest Diagnostics has reached its 52-week high, which TickrTrends currently assesses as overvalued based on its derived valuation metrics. For investors focused on valuation fundamentals, the combination of a stock at elevated price levels and an overvalued rating suggests caution about entry points or holding positions. Monitoring whether the company's Healthcare sector fundamentals can support these elevated prices will be important for determining if the overvaluation represents a temporary or sustained condition.

Read the full story at zacks.com →